• Home
  • For Patients
  • For Site Partners
  • For Sponsors/CROs
  • Our Team
  • Inclusion Advisory Board
  • DAP
  • Contact Us
  • DiversiBlog
  • Translated Site Links
    • DiversiTrials Spanish
    • DiversiTrials French
    • DiversiTrials Arabic
    • DiversiTrials Hindi
    • DiversiTrials Urdu
    • DiversiTrials Japanese
    • DiversiTrials Chinese
    • DiversiTrials Korean
    • DiversiTrials Filipino
    • DiversiTrials Vietnamese
    • DiversiTrials Haitian
  • More
    • Home
    • For Patients
    • For Site Partners
    • For Sponsors/CROs
    • Our Team
    • Inclusion Advisory Board
    • DAP
    • Contact Us
    • DiversiBlog
    • Translated Site Links
      • DiversiTrials Spanish
      • DiversiTrials French
      • DiversiTrials Arabic
      • DiversiTrials Hindi
      • DiversiTrials Urdu
      • DiversiTrials Japanese
      • DiversiTrials Chinese
      • DiversiTrials Korean
      • DiversiTrials Filipino
      • DiversiTrials Vietnamese
      • DiversiTrials Haitian
  • Sign In
  • Create Account

  • My Account
  • Signed in as:

  • filler@godaddy.com


  • My Account
  • Sign out

Signed in as:

filler@godaddy.com

  • Home
  • For Patients
  • For Site Partners
  • For Sponsors/CROs
  • Our Team
  • Inclusion Advisory Board
  • DAP
  • Contact Us
  • DiversiBlog
  • Translated Site Links
    • DiversiTrials Spanish
    • DiversiTrials French
    • DiversiTrials Arabic
    • DiversiTrials Hindi
    • DiversiTrials Urdu
    • DiversiTrials Japanese
    • DiversiTrials Chinese
    • DiversiTrials Korean
    • DiversiTrials Filipino
    • DiversiTrials Vietnamese
    • DiversiTrials Haitian

Account


  • My Account
  • Sign out


  • Sign In
  • My Account

In Memorium: FDA DAP Draft Guidance

 Gone but not forgotten, this draft guidance graced our lives briefly before disappearing into the regulatory abyss.

Disclaimer: This document, which was previously available on the FDA website, has since been removed. It is shared here for entertainment purposes only and should not, in any way, be considered official guidance, draft, or otherwise, from the FDA. This document is provided with full acknowledgment that it is no longer active or valid and is not intended for reference or decision-making in any professional capacity. 

Download Your Copy to Remember Forever
  • Contact Us
  • DiversiTrials Spanish
  • DiversiTrials French
  • DiversiTrials Arabic
  • DiversiTrials Hindi
  • DiversiTrials Urdu
  • DiversiTrials Japanese
  • DiversiTrials Chinese
  • DiversiTrials Korean
  • DiversiTrials Filipino
  • DiversiTrials Vietnamese
  • DiversiTrials Haitian

DiversiTrials

Copyright © 2025 DiversiTrials - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

DeclineAccept

Welcome to DiversiTrials!

We are dedicated to providing equitable research opportunities and would love to connect with you to discuss how we can achieve healthcare equality together!

Contact Us Here!